IRVINE, Calif., Oct. 25, 2006 (PRIMEZONE) -- "As the pharmaceutical and health care market begins to surge under the massive demographic that is the aging Baby Boomers, clinical trials to treat an array of maladies may soon grab headlines," stated SmallCap Sentinel analyst D.R. Clark. "Savvy companies are swiftly executing research and development to service huge needs within this enormous group."
"For example, CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) recently announced that it has initiated a clinical trial to study the safety of a new drug candidate using Cardio Vascu-Grow(tm) as its active ingredient for the treatment of Peripheral Artery Disease (PAD), a disease affecting 8 million Americans," stated Clark. "Undoubtedly, investors and PAD patients alike will be watching intently to see the results of this compelling trial."
Cardio Vascu-Grow(tm) contains a protein that stimulates the growth and production of new blood vessels, a process called angiogenesis.
CardioVascular BioTherapeutics is developing drug candidates with Cardio Vascu-Grow as the active ingredient for products for the treatment of a number of diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA clinical trials underway for advanced coronary artery disease for patients who currently have no or limited treatment options, and for impaired wound healing seen in patients with diabetes. CVBT is also conducting a proof-of-concept trial in Europe in patients with chronic back pain believed to be caused by blockage of lumbar arteries.
An informational report featuring CardioVascular BioTherapeutics is available at: http://stockupticks.com/profiles/2-2-06.html.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is online at http://www.SmallCapSentinel.com.
The report will address issues affecting companies including Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), and AstraZeneca PLC ADS (NYSE:AZN).
Individuals may register to receive free future reports at: http://stockupticks.com/register.html.
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties that affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid nineteen thousand two hundred dollars by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.